FGFR4 and glioblastoma: Strikingly, FGFR4-KD(K504M) expression led to distinct hypersensitivity towards the Arg-Gly-Asp (RGD) motif-specific integrin inhibitor cilengitide in both GBM models (Fig. 5G, Additional File 1: Fig. S9H).